“Mitch has made tremendous contributions to bluebird bio, and his
knowledge of gene therapy has been instrumental to the successful
build-out of our platform capabilities over the last several years,”
stated
“Transitioning out of a full-time role at bluebird was a difficult decision for me, but on a personal level the timing was right,” stated Dr. Finer. “bluebird is in a great position to continue to lead the gene therapy revolution, and I look forward to continuing to work closely with the team as an active member of the SAB. I am extremely proud of the advances we have made over the last five years that have moved the field several big steps closer to realizing the powerful promise that gene therapy holds for patients.”
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and T cell-based
immunotherapy. bluebird bio’s clinical programs include Lenti-D™,
currently in a Phase 2/3 study, the Starbeam Study, for the treatment of
childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in
three clinical studies: a global Phase 1/2 study, the Northstar Study,
for the treatment of beta-thalassemia major; a single-center Phase 1/2
study in
bluebird bio has operations in
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s future business plans, including, the
Company’s plans with respect to Lenti-D, LentiGlobin and its other
product candidates and research programs.. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in the Company’s clinical studies, the risk that
the results of previously conducted studies involving similar product
candidates will not be repeated or observed in ongoing or future studies
involving current product candidates, the risk that our collaboration
with
Availability of other information about bluebird bio
Investors and others should note that we communicate with our
investors and the public using our company website (www.bluebirdbio.com),
our investor relations website (http://www.bluebirdbio.com/investor-splash.html),
including but not limited to investor presentations and FAQs,
Source: bluebird bio, Inc.
Investor Relations:
bluebird bio, Inc
Jim DeTore,
339-499-9382
Chief Financial Officer
or
Media Contact:
Pure
Communications, Inc.
Dan Budwick, 973-271-6085